Triazole Derivatives Modulating GHS Receptors for Obesity Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds fail to effectively modulate growth hormone secretagogue receptors for treating conditions like obesity, growth retardation, and inflammation, as they lack specific biological activity and receptor interaction data.
Innovation Solution
Development of novel triazole derivatives that act as ghrelin analogue ligands for GHS receptors, specifically designed to function as agonists or antagonists to treat conditions mediated by GHS receptors, such as obesity and growth retardation, by binding to GHS-R1a and inducing desired receptor modulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current compounds are used to modulate growth hormone secretagogue receptors, then treatment of conditions like obesity and growth retardation is attempted, but the compounds lack specific biological activity and receptor interaction data
Solution Approach 1:
The patent applies parameter changes by systematically modifying molecular parameters of the compounds, specifically incorporating triazole rings with varying substituents (R1-R6 groups) to optimize binding affinity and biological activity at GHS receptors while maintaining manageable structural complexity
Solution Approach 2:
The patent employs composite materials by creating hybrid molecular structures that combine triazole core structures with various functional groups and substituents, resulting in compounds that exhibit enhanced receptor specificity and biological activity compared to single-structure approaches
2Reliability
If novel triazole derivatives are developed to bind to GHS receptors, then therapeutic effects on obesity and growth retardation are achieved, but the complexity of compound design and synthesis increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments: a core triazole ring system and separate substituent groups (R1-R6), allowing independent optimization of each segment's contribution to receptor binding while simplifying the overall design process
Solution Approach 2:
The patent implements local quality by assigning specific functional properties to different regions of the molecule, where the triazole core provides fundamental binding capability and specific substituents (R1-R6 groups) provide localized enhancements to affinity and selectivity for GHS receptors
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and/or long term regulation of energy balance; short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake; adipogenesis, adiposity and/or obesity; body weight gain and/or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy)".